CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance

CorMedix (NASDAQ: CRMD) reported Q2 EPS of $0.29, $0.06 better than the analyst estimate of $0.23. Revenue for the quarter came in at $101.93 million versus the consensus estimate of $95.62 million.

GUIDANCE:

CorMedix sees FY2026 revenue of $325-345 million, versus the consensus of $334.6 million.

For earnings history and earnings-related data on CorMedix (CRMD) click here.

You May Also Be Interested In

• Ackman adds Netflix, Visa and Mastercard in portfolio revamp
• Cingulate posts wider Q2 loss as SG&A spending more than doubles
• McGraw Hill (MH) Tops Q2 EPS by 11c, Beats on Revenue; Offers FY26 Guidance